Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Origin and function of myofibroblasts in kidney fibrosis.

LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R.

Nat Med. 2013 Aug;19(8):1047-53. doi: 10.1038/nm.3218. Epub 2013 Jun 30.

2.

Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis.

Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS.

Am J Pathol. 2010 Jan;176(1):85-97. doi: 10.2353/ajpath.2010.090517. Epub 2009 Dec 11.

3.

Transforming growth factor β-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis.

Wu CF, Chiang WC, Lai CF, Chang FC, Chen YT, Chou YH, Wu TH, Linn GR, Ling H, Wu KD, Tsai TJ, Chen YM, Duffield JS, Lin SL.

Am J Pathol. 2013 Jan;182(1):118-31. doi: 10.1016/j.ajpath.2012.09.009. Epub 2012 Nov 9.

4.

Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis.

Chen YT, Chang FC, Wu CF, Chou YH, Hsu HL, Chiang WC, Shen J, Chen YM, Wu KD, Tsai TJ, Duffield JS, Lin SL.

Kidney Int. 2011 Dec;80(11):1170-81. doi: 10.1038/ki.2011.208. Epub 2011 Jun 29.

5.

Pericytes in kidney fibrosis.

Ren S, Duffield JS.

Curr Opin Nephrol Hypertens. 2013 Jul;22(4):471-80. doi: 10.1097/MNH.0b013e328362485e. Review.

PMID:
23722183
6.

Origin of myofibroblasts and cellular events triggering fibrosis.

Mack M, Yanagita M.

Kidney Int. 2015 Feb;87(2):297-307. doi: 10.1038/ki.2014.287. Epub 2014 Aug 27. Review.

PMID:
25162398
7.

The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis.

Sun YB, Qu X, Caruana G, Li J.

Differentiation. 2016 Sep;92(3):102-107. doi: 10.1016/j.diff.2016.05.008. Epub 2016 Jun 1. Review.

PMID:
27262400
8.

Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis.

Chang FC, Chou YH, Chen YT, Lin SL.

J Formos Med Assoc. 2012 Nov;111(11):589-98. doi: 10.1016/j.jfma.2012.09.008. Epub 2012 Oct 24. Review.

9.

LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1.

Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, Kobayashi A, Lang RA, Hadjantonakis AK, Moon RT, Duffield JS.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1440-5. doi: 10.1073/pnas.1211179110. Epub 2013 Jan 9. Erratum in: Proc Natl Acad Sci U S A. 2016 Nov 14;:.

10.

Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition.

Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R.

J Am Soc Nephrol. 2008 Dec;19(12):2282-7. doi: 10.1681/ASN.2008050513. Epub 2008 Nov 5.

11.

Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.

Decker M, Martinez-Morentin L, Wang G, Lee Y, Liu Q, Leslie J, Ding L.

Nat Cell Biol. 2017 Jun;19(6):677-688. doi: 10.1038/ncb3530. Epub 2017 May 8.

12.

Distinct sites of renal fibrosis in Crim1 mutant mice arise from multiple cellular origins.

Phua YL, Martel N, Pennisi DJ, Little MH, Wilkinson L.

J Pathol. 2013 Apr;229(5):685-96. doi: 10.1002/path.4155. Epub 2013 Feb 22.

PMID:
23224993
13.

Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis.

Kramann R, Schneider RK, DiRocco DP, Machado F, Fleig S, Bondzie PA, Henderson JM, Ebert BL, Humphreys BD.

Cell Stem Cell. 2015 Jan 8;16(1):51-66. doi: 10.1016/j.stem.2014.11.004. Epub 2014 Nov 20.

14.

The role played by perivascular cells in kidney interstitial injury.

Rojas A, Chang FC, Lin SL, Duffield JS.

Clin Nephrol. 2012 May;77(5):400-8. Review.

15.

Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease.

He J, Xu Y, Koya D, Kanasaki K.

Clin Exp Nephrol. 2013 Aug;17(4):488-97. doi: 10.1007/s10157-013-0781-0. Epub 2013 Feb 21. Review.

PMID:
23430391
16.

Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts.

Barnes JL, Glass WF 2nd.

Contrib Nephrol. 2011;169:73-93. doi: 10.1159/000313946. Epub 2011 Jan 20.

PMID:
21252512
17.

Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition.

Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):E1475-83. doi: 10.1073/pnas.1117988108. Epub 2011 Nov 28.

18.

Hepatocyte growth factor reduces cardiac fibrosis by inhibiting endothelial-mesenchymal transition.

Okayama K, Azuma J, Dosaka N, Iekushi K, Sanada F, Kusunoki H, Iwabayashi M, Rakugi H, Taniyama Y, Morishita R.

Hypertension. 2012 May;59(5):958-65. doi: 10.1161/HYPERTENSIONAHA.111.183905. Epub 2012 Mar 5.

19.

Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis.

Lin SL, Chang FC, Schrimpf C, Chen YT, Wu CF, Wu VC, Chiang WC, Kuhnert F, Kuo CJ, Chen YM, Wu KD, Tsai TJ, Duffield JS.

Am J Pathol. 2011 Feb;178(2):911-23. doi: 10.1016/j.ajpath.2010.10.012.

20.

Pivotal role of pericytes in kidney fibrosis.

Kida Y, Duffield JS.

Clin Exp Pharmacol Physiol. 2011 Jul;38(7):467-73. doi: 10.1111/j.1440-1681.2011.05531.x. Review.

Supplemental Content

Support Center